NOVACYT

About:

NOVACYT develops cellular diagnostics with a growing portfolio of cancer and infectious disease products and services.

Website: http://www.novacyt.com/

Twitter/X: novacytgroup

Top Investors: Kreos Capital, Alto Invest, YA Global Master SPV, Arkeon Gestion

Description:

The Novacyt Group is a rapidly growing, international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company’s lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high quality assays and reagents worldwide. The Group directly serves oncology, microbiology, haematology and serology markets as do its global partners, which include major corporates.